• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Sc Us (Ttgp), Ltd. returned 12,000,124 shares to the company and converted options into 12,000,124 shares (SEC Form 4)

    2/2/26 6:41:52 PM ET
    $LIFE
    Specialty Insurers
    Finance
    Get the next $LIFE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    SC US (TTGP), LTD.

    (Last) (First) (Middle)
    2800 SAND HILL ROAD SUITE 101

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Ethos Technologies Inc. [ LIFE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/30/2026
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 01/30/2026 C(1) 8,027,281 A $0 8,027,281 I Sequoia Capital U.S. Venture Fund XV, L.P.(2)(3)
    Class A Common Stock 01/30/2026 C(1) 337,996 A $0 337,996 I Sequoia Capital U.S. Venture Partners Fund XV (Q), L.P.(2)(3)
    Class A Common Stock 01/30/2026 C(1) 121,541 A $0 121,541 I Sequoia Capital U.S. Venture Partners Fund XV, L.P.(2)(3)
    Class A Common Stock 01/30/2026 C(1) 1,238,282 A $0 1,238,282 I Sequoia Capital U.S. Venture XV Principals Fund, L.P.(2)(3)
    Class A Common Stock 01/30/2026 C(1) 2,132,408 A $0 2,132,408 I Sequoia Capital U.S. Growth Fund VIII, L.P.(2)(3)
    Class A Common Stock 01/30/2026 C(1) 142,616 A $0 142,616 I See Footnotes(4)(5)(6)
    Class A Common Stock 01/30/2026 D(1) 8,027,281 D $0 0 I Sequoia Capital U.S. Venture Fund XV, L.P.(2)(3)
    Class A Common Stock 01/30/2026 D(1) 337,996 D $0 0 I Sequoia Capital U.S. Venture Partners Fund XV (Q), L.P.(2)(3)
    Class A Common Stock 01/30/2026 D(1) 121,541 D $0 0 I Sequoia Capital U.S. Venture Partners Fund XV, L.P.(2)(3)
    Class A Common Stock 01/30/2026 D(1) 1,238,282 D $0 0 I Sequoia Capital U.S. Venture XV Principals Fund, L.P.(2)(3)
    Class A Common Stock 01/30/2026 D(1) 2,132,408 D $0 0 I Sequoia Capital U.S. Growth Fund VIII, L.P.(2)(3)
    Class A Common Stock 01/30/2026 D(1) 142,616 D $0 0 I See Footnotes(4)(5)(6)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Series A-2 Preferred Stock (1) 01/30/2026 C(1) 1,897,656 (1) (1) Class A Common Stock 1,897,656 $0 0 I Sequoia Capital U.S. Venture Fund XV, L.P.(2)(3)
    Series A-2 Preferred Stock (1) 01/30/2026 C(1) 79,975 (1) (1) Class A Common Stock 79,975 $0 0 I Sequoia Capital U.S. Venture Partners Fund XV (Q), L.P.(2)(3)
    Series A-2 Preferred Stock (1) 01/30/2026 C(1) 28,725 (1) (1) Class A Common Stock 28,725 $0 0 I Sequoia Capital U.S. Venture Partners Fund XV, L.P.(2)(3)
    Series A-2 Preferred Stock (1) 01/30/2026 C(1) 291,875 (1) (1) Class A Common Stock 291,875 $0 0 I Sequoia Capital U.S. Venture XV Principals Fund, L.P.(2)(3)
    Series A-2 Preferred Stock (1) 01/30/2026 C(1) 142,616 (1) (1) Class A Common Stock 142,616 $0 0 I See Footnotes(4)(5)(6)
    Series A Preferred Stock (1) 01/30/2026 C(1) 4,767,653 (1) (1) Class A Common Stock 4,767,653 $0 0 I Sequoia Capital U.S. Venture Fund XV, L.P.(2)(3)
    Series A Preferred Stock (1) 01/30/2026 C(1) 200,936 (1) (1) Class A Common Stock 200,936 $0 0 I Sequoia Capital U.S. Venture Partners Fund XV (Q), L.P.(2)(3)
    Series A Preferred Stock (1) 01/30/2026 C(1) 72,174 (1) (1) Class A Common Stock 72,174 $0 0 I Sequoia Capital U.S. Venture Partners Fund XV, L.P.(2)(3)
    Series A Preferred Stock (1) 01/30/2026 C(1) 733,307 (1) (1) Class A Common Stock 733,307 $0 0 I Sequoia Capital U.S. Venture XV Principals Fund, L.P.(2)(3)
    Series B Preferred Stock (1) 01/30/2026 C(1) 1,124,709 (1) (1) Class A Common Stock 1,124,709 $0 0 I Sequoia Capital U.S. Venture Fund XV, L.P.(2)(3)
    Series B Preferred Stock (1) 01/30/2026 C(1) 47,400 (1) (1) Class A Common Stock 47,400 $0 0 I Sequoia Capital U.S. Venture Partners Fund XV (Q), L.P.(2)(3)
    Series B Preferred Stock (1) 01/30/2026 C(1) 17,025 (1) (1) Class A Common Stock 17,025 $0 0 I Sequoia Capital U.S. Venture Partners Fund XV, L.P.(2)(3)
    Series B Preferred Stock (1) 01/30/2026 C(1) 172,989 (1) (1) Class A Common Stock 172,989 $0 0 I Sequoia Capital U.S. Venture XV Principals Fund, L.P.(2)(3)
    Series C Preferred Stock (1) 01/30/2026 C(1) 180,988 (1) (1) Class A Common Stock 180,988 $0 0 I Sequoia Capital U.S. Venture Fund XV, L.P.(2)(3)
    Series C Preferred Stock (1) 01/30/2026 C(1) 7,627 (1) (1) Class A Common Stock 7,627 $0 0 I Sequoia Capital U.S. Venture Partners Fund XV (Q), L.P.(2)(3)
    Series C Preferred Stock (1) 01/30/2026 C(1) 2,739 (1) (1) Class A Common Stock 2,739 $0 0 I Sequoia Capital U.S. Venture Partners Fund XV, L.P.(2)(3)
    Series C Preferred Stock (1) 01/30/2026 C(1) 27,837 (1) (1) Class A Common Stock 27,837 $0 0 I Sequoia Capital U.S. Venture XV Principals Fund, L.P.(2)(3)
    Series C Preferred Stock (1) 01/30/2026 C(1) 1,917,944 (1) (1) Class A Common Stock 1,917,944 $0 0 I Sequoia Capital U.S. Growth Fund VIII, L.P.(2)(3)
    Series D Preferred Stock (1) 01/30/2026 C(1) 56,275 (1) (1) Class A Common Stock 56,275 $0 0 I Sequoia Capital U.S. Venture Fund XV, L.P.(2)(3)
    Series D Preferred Stock (1) 01/30/2026 C(1) 2,058 (1) (1) Class A Common Stock 2,058 $0 0 I Sequoia Capital U.S. Venture Partners Fund XV (Q), L.P.(2)(3)
    Series D Preferred Stock (1) 01/30/2026 C(1) 878 (1) (1) Class A Common Stock 878 $0 0 I Sequoia Capital U.S. Venture Partners Fund XV, L.P.(2)(3)
    Series D Preferred Stock (1) 01/30/2026 C(1) 12,274 (1) (1) Class A Common Stock 12,274 $0 0 I Sequoia Capital U.S. Venture XV Principals Fund, L.P.(2)(3)
    Series D Preferred Stock (1) 01/30/2026 C(1) 214,464 (1) (1) Class A Common Stock 214,464 $0 0 I Sequoia Capital U.S. Growth Fund VIII, L.P.(2)(3)
    Class B Common Stock (1) 01/30/2026 A(1) 8,027,281 (1) (1) Class A Common Stock 8,027,281 $0 8,027,281 I Sequoia Capital U.S. Venture Fund XV, L.P.(2)(3)
    Class B Common Stock (1) 01/30/2026 A(1) 337,996 (1) (1) Class A Common Stock 337,996 $0 337,996 I Sequoia Capital U.S. Venture Partners Fund XV (Q), L.P.(2)(3)
    Class B Common Stock (1) 01/30/2026 A(1) 121,541 (1) (1) Class A Common Stock 121,541 $0 121,541 I Sequoia Capital U.S. Venture Partners Fund XV, L.P.(2)(3)
    Class B Common Stock (1) 01/30/2026 A(1) 1,238,282 (1) (1) Class A Common Stock 1,238,282 $0 1,238,282 I Sequoia Capital U.S. Venture XV Principals Fund, L.P.(2)(3)
    Class B Common Stock (1) 01/30/2026 A(1) 2,132,408 (1) (1) Class A Common Stock 2,132,408 $0 2,132,408 I Sequoia Capital U.S. Growth Fund VIII, L.P.(2)(3)
    Class B Common Stock (1) 01/30/2026 A(1) 142,616 (1) (1) Class A Common Stock 142,616 $0 142,616 I See Footnotes(4)(5)(7)
    1. Name and Address of Reporting Person*
    SC US (TTGP), LTD.

    (Last) (First) (Middle)
    2800 SAND HILL ROAD SUITE 101

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    SEQUOIA CAPITAL U.S. SCOUT SEED FUND 2013, L.P.

    (Last) (First) (Middle)
    2800 SAND HILL ROAD SUITE 101

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Sequoia Capital U.S. Scout IV, L.L.C

    (Last) (First) (Middle)
    2800 SAND HILL ROAD SUITE 101

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Nalrena, LLC

    (Last) (First) (Middle)
    2800 SAND HILL ROAD SUITE 101

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Spelunker Channel Holdings, LLC

    (Last) (First) (Middle)
    2800 SAND HILL ROAD SUITE 101

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. Upon the closing of the Issuer's IPO, all shares of Series A-2, Series A, Series B, Series C, and Series D Preferred Stock automatically converted into shares of Class A Common Stock of the Issuer (the "Class A Conversion") based on the IPO price of the Class A Common Stock. Immediately following the Class A Conversion, shares of the Class A Common Stock included in this Form 4 exchanged at a 1:1 ratio for shares of Class B Common Stock. Each share of Class B Common Stock is convertible at the option of the holder thereof into one share of Class A Common Stock and otherwise in accordance with the terms of the Issuer's Certificate of Incorporation. The securities have no expiration date.
    2. SC US (TTGP), Ltd. is (i) the general partner of SC U.S. Growth VIII Management, L.P., which is the general partner of Sequoia Capital U.S. Growth Fund VIII, L.P. (GFVIII), and (ii) the general partner of SC U.S. Venture XV Management, L.P., which is the general partner of Sequoia Capital U.S. Venture Fund XV, L.P., Sequoia Capital U.S. Venture Partners Fund XV (Q), L.P., Sequoia Capital U.S. Venture Partners Fund XV, L.P., and Sequoia Capital U.S. Venture XV Principals Fund, L.P. (collectively, the XV Funds).
    3. [continued from Footnote 2] As a result, SC US (TTGP), Ltd. may be deemed to share voting and dispositive power with respect to the shares held by GFVIII and the XV Funds. Each of SC US (TTGP), Ltd., SC U.S. Growth VIII Management, L.P. and SC U.S. Venture XV Management, L.P. disclaims beneficial ownership of the shares held by GFVIII and the XV Funds, as applicable, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
    4. SC US SSF 2013 (TTGP), L.L.C. is the general partner of SC U.S. Scout Seed Fund 2013 Management, L.P., which is the general partner of Sequoia Capital U.S. Scout Seed Fund 2013, L.P., which wholly owns Sequoia Capital U.S. Scout Fund IV, L.L.C., which in turn wholly owns Nalrena, L.L.C. and Spelunker Channel Holdings, LLC (collectively, the Scout Funds). As a result, SC US SSF 2013 (TTGP), L.L.C., SC U.S. Scout Seed Fund 2013 Management, L.P., Sequoia Capital U.S. Scout Seed Fund 2013, L.P., and Sequoia Capital U.S. Scout Fund IV, L.L.C. may be deemed to share voting and dispositive power with respect to the shares held by the Scout Funds.
    5. [continued from Footnote 4] Each of SC US SSF 2013 (TTGP), L.L.C., SC U.S. Scout Seed Fund 2013 Management, L.P., Sequoia Capital U.S. Scout Seed Fund 2013, L.P., and Sequoia Capital U.S. Scout Fund IV, L.L.C. disclaims beneficial ownership of the securities held by the Scout Funds except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
    6. Includes 79,246 shares of Class A Common Stock held by Spelunker Channel Holdings, LLC and 63,370 shares of Class A Common Stock held by Nalrena LLC.
    7. Includes 79,246 shares of Class B Common Stock held by Spelunker Channel Holdings, LLC and 63,370 shares of Class B Common Stock held by Nalrena LLC.
    Remarks:
    2 of 2 (1) /s/ Jung Yeon Son, by power of attorney for Roelof Botha, a Director of SC US SSF 2013 (TTGP), L.L.C., the General Partner of SC U.S. Scout Seed Fund 2013 Management, L.P., the General Partner of Sequoia Capital U.S. Scout Seed Fund 2013, L.P., which wholly owns Sequoia Capital U.S. Scout Fund IV, L.L.C. (2)/s/ Jung Yeon Son, by power of attorney for Roelof Botha, a Director of SC US SSF 2013 (TTGP), L.L.C., the General Partner of SC U.S. Scout Seed Fund 2013 Management, L.P., the General Partner of Sequoia Capital U.S. Scout Seed Fund 2013, L.P., which wholly owns Sequoia Capital U.S. Scout Fund IV, L.L.C., which wholly owns Nalrena, L.L.C. (3)/s/ Jung Yeon Son, by power of attorney for Roelof Botha, a Director of SC US SSF 2013 (TTGP), L.L.C., the General Partner of SC U.S. Scout Seed Fund 2013 Management, L.P., the General Partner of Sequoia Capital U.S. Scout Seed Fund 2013, L.P., which wholly owns Sequoia Capital U.S. Scout Fund IV, L.L.C., which wholly owns Spelunker Channel Holdings,LLC
    /s/ Jung Yeon Son, by power of attorney for Roelof Botha, a Director of SC US (TTGP), Ltd. 02/02/2026
    /s/ Jung Yeon Son, by power of attorney for Roelof Botha, a Director of SC US SSF 2013 (TTGP), L.L.C., the General Partner of SC U.S. Scout Seed Fund 2013 Management, L.P., the General Partner of Sequoia Capital U.S. Scout Seed Fund 2013, L.P. 02/02/2026
    /s/ Jung Yeon Son, by power of attorney for Roelof Botha, for Sequoia Capital U.S. Scout Fund IV, L.L.C. [see Remarks (1)] 02/02/2026
    /s/ Jung Yeon Son, by power of attorney for Roelof Botha, for Nalrena, L.L.C. [see Remarks (2)] 02/02/2026
    /s/ Jung Yeon Son, by power of attorney for Roelof Botha, for Spelunker Channel Holdings, LLC [see Remarks (3)] 02/02/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LIFE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIFE

    DatePrice TargetRatingAnalyst
    7/5/2023Outperform → Perform
    Oppenheimer
    11/11/2021$18.00 → $11.00Buy
    HC Wainwright & Co.
    11/11/2021$18.00 → $11.00Action List Buy
    HC Wainwright & Co.
    10/12/2021$22.00Outperform
    RBC Capital
    9/21/2021$19.00Overweight
    Piper Sandler
    9/14/2021$20.00 → $21.00Buy
    Roth Capital
    9/14/2021$14.00 → $20.00Outperform
    Oppenheimer
    9/13/2021$13.00 → $18.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LIFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Ethos Files Registration Statement for Proposed Initial Public Offering

    AUSTIN, Texas, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Ethos intends to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol "LIFE." Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. BofA Securities,

    9/26/25 1:50:31 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Ethos and Lifeforce Team Up to Help Policyholders Live Longer, Healthier Lives

    AUSTIN, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a partnership with Lifeforce, the largest longevity medicine platform. Through this collaboration, Ethos policyholders will be able to gain valuable insights into their own health at affordable prices, starting with a $250 benefit to Lifeforce's Diagnostic offering, that includes at-home biomarker testing, access to board-certified longevity physicians, personalized treatment protocols, and ongoing health coaching. Together, Ethos and Lifeforce aim to help more families safeguard their future - uniting financial protection

    8/13/25 8:00:00 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    SEC Filings

    View All

    SEC Form 8-K filed by Ethos Technologies Inc.

    8-K - Ethos Technologies Inc. (0001788451) (Filer)

    2/2/26 7:02:49 AM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form 424B4 filed by Ethos Technologies Inc.

    424B4 - Ethos Technologies Inc. (0001788451) (Filer)

    1/29/26 9:55:44 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form S-8 filed by aTyr Pharma Inc.

    S-8 - Ethos Technologies Inc. (0001788451) (Filer)

    1/29/26 8:09:47 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Botha Roelof bought $4,949,975 worth of shares (260,525 units at $19.00), converted options into 12,000,124 shares and returned 12,000,124 shares to the company (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/2/26 6:36:37 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Director Wheeler William J bought $4,949,975 worth of shares (260,525 units at $19.00), increasing direct ownership by 2,481% to 271,025 units (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    1/30/26 8:49:26 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Director Mullin Mark W. bought $99,997 worth of shares (5,263 units at $19.00), increasing direct ownership by 43% to 17,451 units (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    1/30/26 8:48:09 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Softbank Group Corp. converted options into 2,697,089 shares (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/3/26 9:00:15 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Large owner Accel Growth Fund Iv L.P. converted options into 7,143,886 shares (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/2/26 9:08:31 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Large owner Sc Us (Ttgp), Ltd. returned 12,000,124 shares to the company and converted options into 12,000,124 shares (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/2/26 6:41:52 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    aTyr Pharma downgraded by Oppenheimer

    Oppenheimer downgraded aTyr Pharma from Outperform to Perform

    7/5/23 7:41:57 AM ET
    $LIFE
    Specialty Insurers
    Finance

    HC Wainwright & Co. reiterated coverage on aTyr Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of aTyr Pharma with a rating of Buy and set a new price target of $11.00 from $18.00 previously

    11/11/21 6:10:41 AM ET
    $LIFE
    Specialty Insurers
    Finance

    HC Wainwright & Co. reiterated coverage on aTyr Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of aTyr Pharma with a rating of Action List Buy and set a new price target of $11.00 from $18.00 previously

    11/11/21 6:10:41 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Financials

    Live finance-specific insights

    View All

    aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

    Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD currently enrolling. Ended 2023 with $101.7 million in cash, cash equivalents and investments. Company to host conference call and webcast today, March 14th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged

    3/14/24 4:00:00 PM ET
    $LIFE
    Specialty Insurers
    Finance

    aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

    SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 14, 2024Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI834bef07b22642ae8be51b7

    2/28/24 8:00:00 AM ET
    $LIFE
    Specialty Insurers
    Finance

    aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results

    SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate update after the market close on Thursday, March 9, 2023. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 9, 2023Time: 5:00 p.m. EST / 2:00 p.m. PSTDial-In Registration: https://register.vevent.com/register/BI01f8362bebee42539116051

    3/2/23 8:00:00 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Insurtech Leader Ethos Adds Industry Veteran William Wheeler to Board of Directors

    AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the appointment of William J. Wheeler to its Board of Directors. Mr. Wheeler, a seasoned executive with deep expertise across insurance, retirement services, and investment banking, joins Ethos' distinguished board, further strengthening Ethos' governance and strategic guidance as the company continues its rapid growth and innovation. Mr. Wheeler brings more than three decades of leadership experience in the financial services industry. He most recently served as Vice Chairman of Athene Holding Ltd. (NYSE:ATH), a leadin

    7/30/25 11:00:00 AM ET
    $EVR
    $LIFE
    $ATH
    Investment Managers
    Finance
    Specialty Insurers
    Life Insurance

    aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

    SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Wayne A. I. Frederick, M.D., as an advisor to the company. Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023. "We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Dr. Frederick's clinical background combined with

    1/18/24 8:00:00 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $LIFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/14/24 1:43:55 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/13/24 4:30:17 PM ET
    $LIFE
    Specialty Insurers
    Finance

    SEC Form SC 13G/A filed by aTyr Pharma Inc. (Amendment)

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    2/9/24 8:35:54 AM ET
    $LIFE
    Specialty Insurers
    Finance